There is now considerable preclinical evidence that glutamate acting via
the NMDA receptor is involved in the transmission of nociceptive
information and in the triggering mechanisms for hyperalgesia and
allodynia. This evidence allows rational development of a new class of
analgesic drugs that act as antagonists of the NMDA receptor, supported
by emerging evidence with existing excitatory amino acid antagonists.
L
Includes supplementary material: sn.pub/extras
Dalip J.S. Sirinathsinghji
analgesics brain chemistry development drugs future molecular biology neuropeptides pain pharmacology physiology research spinal cord therapy treatment